跳至主要内容
临床试验/EUCTR2013-004961-14-SE
EUCTR2013-004961-14-SE进行中(未招募)1 期

Pilot study to investigate the mode of action (MoA) of Uro-Vaxom® on a molecular level in pre-menopausal women suffering from recurrent urinary tract infections (rUTI) - OM-89 Modes of action study in women with recurrent UTI

Kliniken Kärnan Urology Centre0 个研究点目标入组 10 人开始时间: 2014年4月29日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • Otherwise healthy pre-menopausal females who are naïve to OM-89 prophylaxis (>18 years old) suffering from recurrent non-febrile lower UTI (=3 UTIs in previous year. UTI episodes should be documented by repeated cultures and at least 2 clinical symptoms and there should be a minimum interval of 2 weeks between each infection episode).
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 10
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - Diabetes mellitus type 1
  • - Poorly controlled diabetes mellitus type 2
  • - Treatment of malignant diseases in the past two years
  • - Corticosteroid treatment
  • - Auto-immune disorders
  • - Immune deficiency or immune compromised conditions
  • - Multiple sclerosis
  • - Women: pregnant or intending to be pregnant and not using acceptable contraceptives, menopausal status
  • - Previous OM-89 treatment

研究者

发起方
Kliniken Kärnan Urology Centre

相似试验